5 completed, 1 not yet recruiting, 1 suspended, 1 terminated. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Not yet recruiting 1, Suspended 1, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Suspended 1 |
Follow piperaquine: new trials by email Literature Review of piperaquine trials Research Report on piperaquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax) - Malaria | Phase 1 | Not yet recruiting | University of Oxford | 24 | 2026-11-01 | 2026-08-05 |
| In-vivo Transmission Model in Semi-immune Adults Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg)., Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days. - Controlled Human Malaria Infection, Induced Blood Stage Malaria Infection | Phase 1 | Unknown | Ifakara Health Institute | 24 | 2024-01-09 | 2023-12-15 |
| Controlled Human Malaria Infection Transmission Model - Phase A PfSPZ Challenge, Sulfadoxine-Pyrimethamine, Piperaquine - Malaria,Falciparum | Phase 1 / Phase 2 | Suspended | University of Oxford | 44 | 2022-08-22 | 2024-05-23 |
| A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate Pyronaridine Tetraphosphate, Piperaquine tetraphosphate, Placebo - Healthy | Phase 1 | Completed | Medicines for Malaria Venture | 37 | 2022-02-14 | 2024-05-10 |
| Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP 480 mg Piperaquine phosphate, 640 mg Piperaquine phosphate, 200 mg OZ 439 - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 24 | 2018-04-23 | 2024-05-10 |
| Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1 Sulfadoxine-pyrimethamine (low dose), Piperaquine (low dose), Sulfadoxine-pyrimethamine (high dose) - Malaria | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 29 | 2016-06-01 | 2018-03-23 |
| Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos KAE609, Piperaquine Phosphate - Plasmodium Falciparum Malaria | Phase 1 | Terminated | Novartis Pharmaceuticals | 8 | 2015-07-01 | 2019-07-23 |
| Experimental Falciparum Transmission to Anopheles Administration of the malaria inoculum, Piperaquine Phosphate 480 mg - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 6 | 2015-04-01 | 2020-05-26 |
| Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects 100mg OZ439 single oral dose, Placebo, 300 mg OZ439 single oral dose - Healthy | Phase 1 | Completed | Medicines for Malaria Venture | 59 | 2012-09-01 | 2015-01-21 |
Malaria (5) · Malaria, Falciparum (2)
Medicines for Malaria Venture (4) · University of Oxford (2) · Ifakara Health Institute (1) · Novartis Pharmaceuticals (1) · Radboud University Medical Center (1)
Australia (3) · Kenya (1) · Netherlands (1) · Switzerland (1) · Tanzania (1) · Thailand (1) · United Kingdom (1)
Ally Olotu, MD,Dphil (1) · James McCarthy, MD FRACP (1) · James McCarthy, Prof (1) · Milko M Radicioni, MD PhD (1) · Rebecca Webster, Dr (1) · Stephan Chalon, MD PhD (1) · Ulrike Lorch, MD (1)
PMID 29389671, PMID 29482720, PMID 31146732, PMID 33199389, PMID 39609822, PMID 40689586